— ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) reported Q4 2019 loss of $0.34 per share, vs. $0.36 expected.
— Revenue grew 65% to $98.3 million vs. $97.76 million expected.
— For FY20, NUPLAZID sales is expected to be between $440 million and $470 million.
— For fiscal 2020, GAAP R&D expense is expected to be between $270 and $285 million and GAAP SG&A expense is expected to be between $440 and $460 million.
— ACAD shares rose about 4% following the earnings announcement.
Broadcom Limited (NASDAQ: AVGO) reported first quarter 2021 earnings results today. Total revenue increased 14% year-over-year to $6.65 billion. GAAP net income was $1.3 billion, or $3.05 per share, compared
Retail giant Costco Wholesale Corporation (NASDAQ: COST) reported higher earnings and revenues for the second quarter of 2021. Earnings missed analysts’ expectations, while sales beat. Net profit was $951 million
With the corporate world rapidly shifting to cloud-native computing after the virus outbreak changed work culture and the way businesses operate, technology providers are aggressively innovating their offerings. Hewlett Packard